Usefulness of Topical Ivermectin and Carrageenan to Prevent Contagion of Covid 19 (IVERCAR)
et al., NCT04425850, NCT04425850, Oct 2020
Prophylaxis study using ivermectin and carrageenan showing 0 of 131 cases from treated healthcare workers, compared to 11 of 98 control.
The effect is likely to be primarily due to ivermectin - the author has later reported that carrageenan is not necessary1.
See2 for discussion of issues with this trial.
Targeted administration to the respiratory tract provides treatment directly
to the typical source of initial SARS-CoV-2 infection and replication, and
allows for rapid onset of action, higher local drug concentration, and reduced systemic side effects.
This study is excluded in meta
analysis:
combined treatment may significantly contribute to efficacy, concern about potential data issues.
Study covers iota-carrageenan and ivermectin.
|
risk of case, 96.3% lower, RR 0.04, p < 0.001, treatment 0 of 131 (0.0%), control 11 of 98 (11.2%), NNT 8.9, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Carvallo et al., 19 Oct 2020, prospective, Argentina, preprint, 1 author, this trial uses multiple treatments in the treatment arm (combined with iota-carrageenan) - results of individual treatments may vary, trial NCT04425850 (history).
